This on-demand webinar focuses on highlighting barriers to living with NAFLD and looks at options for addressing them, through interactive debates and expert talks on current evidence and management strategies, including lifestyle interventions.  Learn about the burning topic of NAFLD from a range of perspectives: patient representative, doctor, liver nurse, dietician, and physiotherapist, and take part in small group discussions.  

Target Audience  

This on-demand webinar is intended for nurses and AHPs, but all members of the liver community are welcome.  

 Learning Objectives  

  • Gaining an understanding of the pathophysiology of NAFLD   
  • Reviewing methods for treating NAFLD, the evidence for these methods, and their clinical usefulness 
  • Reviewing the effectiveness of exercise, nutrition, and lifestyle adjustments in the management of NAFLD and the barriers to implementing strategies 
  • Considering the implications of living with NAFLD and its impact on management and care  


Time Title


Dr Patrizia Künzler-Heule, chair of EASL Nurses’ & AHP taskforce, University of Basel, Switzerland


Living with NAFLD. What do HCP’s need to know

Mr. Christian Price, patient representative, Birmingham, United Kingdom




NAFLD in a nutshell

Prof. Elisabetta Bugianesi, physician, gastroenterologist, Torino University, Italy




Can exercise make an impact?

Dr Kate Hallsworth, physiotherapist Newcastle biomedical research centre, United Kingdom




The scope of nutritional management in NAFLD

Ms. Tayla Robertson, dietitian, Princess Alexandra Hospital, Brisbane, Australia




The impact of treatment on my life

Mr. Christian Price, patient representative, Birmingham, United Kingdom


Summary of webinar and close

Ms. Jennifer Towey, member of EASL Nurses’ & AHP taskforce, Birmingham, United Kingdom




Christian Price My name is Christian Price, a former history teacher before I fell ill with NAFLD. I had my transplant in February 2018 followed by a sleeve gastrectomy in 2020 to relieve pressure on my new liver. I currently work as a bookkeeper but am now hoping to return to teaching in the near future. I am a member of the Queen Elizabeth hospital patient participation group for liver and hi research and am helping on the exakt project with Dr Matt Armstrong as a patient representative.
Elisabetta Bugianesi Dr Bugianesi MD, PhD, is currently Professor of Gastroenterology and Scientific Director of the Dept of Medical Sciences at the University of Turin in Italy. Dr Bugianesi received her MD and her Internal Medicine Residency at the University of Bologna. Her post-graduate training included a PhD fellowship at Case Western Reserve University, Cleveland, USA, from 1995 to 1998 where she became expert in the use of stable isotopes to study in vivo metabolism. Dr Bugianesi is an international acknowledged expert on Non-Alcoholic Fatty Liver Disease (NAFLD) with over 15-years experience. She contributed in the field with work describing the metabolic mechanisms of insulin resistance related to the onset and progression of liver damage, the natural history of the disease (including the first demonstration of HCC as a complication of NASH), the development of non-invasive markers of fibrosis, and the involvement in several trials for the treatment of NAFLD/NASH. Her contribution to science is testified by over 200 publications, an H Index = 66, N. Citations = 20730 (Scopus).
Kate Hallsworth Dr Kate Hallsworth is an NIHR Clinical Lecturer and a Senior Research Physiotherapist within the Liver Unit at Newcastle upon Tyne Hospitals NHS Foundation Trust (NuTH). She has published world-leading research in the field of lifestyle management for patients with non-alcoholic fatty liver disease (NAFLD). More recently, her research has looked at why lifestyle interventions are not being optimised in clinical practice and what tools are necessary to aid healthcare professionals to support patients to make lifestyle changes. She led the development of an evidence-based NAFLD-specific digital intervention (VITALISE- interVention to promote lIfesTyle change in non-Alcoholic fatty LIver diseaSE) which was co-designed with patients and will be trialled within the NHS in the coming months.